Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibodydependent cell-mediated cytotoxicity against prostate cancer cells

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Pandey, Janardan P ^a   Namboodiri, Aryan M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ADCC; Anti MUC1 antibodies; Fc R genotypes; GM allotypes; HuHMFG1; Prostate cancer

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIIA; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; MUCIN 1; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; EPISTASIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PROSTATE CANCER;

EID: 84899083197     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27317     Document Type: Article

References (19)

1. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82:249-93; PMID:14975259; http://dx.doi.org/10.1016/S0065-2776(04)82006-6.
2. Von Mensdorff-Pouilly S, Moreno M, Verheijen RH. Natural and induced humoral responses to MUC1. Cancers (Basel) 2011; 3:3073-103; PMID:24212946; http://dx.doi.org/10.3390/cancers3033073.
3. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
4. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103:97-100; PMID:12455059; http://dx.doi.org/10.1002/ijc.10801.
5. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998; 46:245-52; PMID:9690452; http://dx.doi.org/10.1007/s002620050484.
6. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161:589-94; PMID:10673204; http://dx.doi. org/10.1164/ajrccm.161.2.9905028.
7. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18:574-83; PMID:10653872.
8. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P. Antibody-dependent cellmediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001; 93:97-106; PMID:11391628; http://dx.doi.org/10.1002/ijc.1286.
9. Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2007; 257:47-55; PMID:17692456; http://dx.doi.org/10.1016/j. canlet.2007.06.016.
10. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004; 101:811-6; PMID:14711987; http://dx.doi.org/10.1073/pnas.0304146101.
11. Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, Mucci LA. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007; 97:730-4; PMID:17726465; http://dx.doi.org/10.1038/sj.bjc.6603944.
12. Pandey JP, Li Z. The forgotten tale of immunoglobulin allotypes in cancer risk and treatment. Exp Hematol Oncol 2013; 2:6; PMID:23425356; http://dx.doi. org/10.1186/2162-3619-2-6.
13. Schanfield MS, van Loghem E. Human immunoglobulin allotypes. In: Weir DM (ed) Handbook of Experimental Immunology. Boston: Blackwell 1986; 94.1-94.18.
14. MacDonald IM, Dumble LJ, Jack I, Clunie GJ. Inhibition of whole blood antibody dependent cellular cytotoxicity by heat aggregated human IgG. J Immunol Methods 1981; 46:69-76; PMID:7288199; http://dx.doi.org/10.1016/0022-1759(81)90334-3.
15. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi. org/10.1073/pnas.0508123103.
16. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744.
17. Brüggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166:1351-61; PMID:3500259; http://dx.doi.org/10.1084/jem.166.5.1351.
18. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011; 17:6822-30; PMID:21878535; http://dx.doi. org/10.1158/1078-0432.CCR-11-1151.
19. Pandey JP, Kistner-Griffin E, Namboodiri AM, Black L, Jobim M. Suggestive evidence that Fc variants of IgG2 and FcγRIIα loci interact to contribute to the risk of prostate cancer. Hum Immunol 2013; 74:1656-8http://dx.doi.org/10.1016/j.humimm.2013.08.280; PMID:23994584.